NCT03709121

A Methodology Development Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber

An Exploratory Clinical Trial Evaluating Reproxalap Ophthalmic Solutions (0.25% and 0.5%) in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber (EEC)

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 70 (actual)
• Sponsor: Aldeyra Therapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

An Exploratory Clinical Trial Evaluating Reproxalap Ophthalmic Solutions (0.25% and 0.5%) in Subjects with Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber (EEC)

Conditions

• Conjunctivitis, Allergic

Interventions

Type	Name	Description
DRUG	Reproxalap Ophthalmic Solution (0.25%)	Reproxalap Ophthalmic Solution (0.25%) dosed twice.
DRUG	Reproxalap Ophthalmic Solution (0.5%)	Reproxalap Ophthalmic Solution (0.5%) dosed twice.
DRUG	Vehicle Ophthalmic Solution	Vehicle Ophthalmic Solution dosed twice.

Timeline

• Start date: 2018-10-02
• Primary completion: 2019-03-20
• Completion: 2019-03-20
• First posted: 2018-10-17
• Last updated: 2025-02-24
• Results posted: 2025-02-24

Locations

1 site across 1 country: Canada

Regulatory

• FDA-regulated drug study